A Phase II, Randomized, Controlled, Open-Label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG [human chorionic gonadotropin] or Recombinant FSH [follicle stimulating hormone] [Urofollitropin] Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Chorionic gonadotropin; Corifollitropin alfa; Urofollitropin
- Indications Infertility
- Focus Therapeutic Use
- Sponsors Organon; Schering-Plough
- 11 Jul 2008 New trial record.